EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment failure with out-patient therapy of community-acquired pneumonia



Treatment failure with out-patient therapy of community-acquired pneumonia



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 472



We conducted a retrospective study to evaluate predictors of outpatient antimicrobial treatment failure in community-acquired pneumonia. From July 2000 to April 2001 hospitalized pts with a diagnosis of CAP were identified. Charts of 72 pts who had received antibiotics prior to admission were evaluated. Data was collected on outpatient antibiotic therapy, comorbidity, sign/symptoms of pneumonia, Pneumonia Severity Index (PSI), and pathogen susceptibility. Both genders were represented equally and age groups were: 25%>50 yrs, 26% 50-70 yrs, and 49%>70 yrs. 58% of the pts were smokers. COPD/asthma was the most common comorbid condition (50%) followed by malignancy (28%) and diabetes (24%). The most frequent symptoms were cough (93%), dyspnea (69%), sputum production (67%), fever (60%), chills (30%), and chest pain (30%), and 50% had leukocytosis. S. pneumoniae was isolated from 19% of the pts. Based on PSI scoring system 50% of the pts were in the low (PSI<90), 37% in moderate (PSI 90-130) and 13% in high (PSI<130) risk groups. The most commonly used class of antibiotic prior to admission was macrolide 44% (azithromycin n=20, clarithromycin n=8, erythromycin n=5) followed by quinolone 23%, penicillin 13%, and cephalosporin 9%. The length of therapy varied from 1-14 days with 81% receiving antibiotic for >3 days. Twelve percent of the pts had no comorbid conditions while 78% had one or more coexisting illnesses. Among the individuals without co-morbid illness with documented S. pneumoniae, 67% were resistant to the antibiotic selected for therapy. 35% of macrolide (azithromycin n=3, clarithromycin n=l, and erythromycin n=2) and 50% of PCN failure pts had susceptible pathogens, suggesting other reasons for treatment failure. In conclusion PSI scoring was not a good predictor of admission making decision. Age>70, COPD/asthma, underlying malignancy, and diabetes were risk factors for outpatient treatment failure of CAP.

(PDF 0-2 workdays service: $29.90)

Accession: 035980158

Download citation: RISBibTeXText



Related references

Treatment failure in community-acquired pneumonia: coccidioidomycosis in a traveler patient. Revista Chilena de Infectologia 30(6): 669-672, 2014

The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest 122(3): 920-929, 2002

What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia?. Infectious Disease Clinics of North America 27(1): 157-175, 2013

Corticosteroid therapy for uncomplicated community-acquired pneumonia: weak and unreliable benefits for the patient as well as for the community. Medecine et Maladies Infectieuses 41(11): 631-632, 2012

Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respiratory Medicine 94(2): 97-105, 2000

Treatment failure in community-acquired pneumonia. Chest 132(4): 1348-1355, 2007

Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines. Tropical Medicine & International Health 19(11): 1310-1320, 2014

Community-acquired pneumonia: attitude case of treatment failure. Revue Medicale Suisse 1(36): 2333-4, 2336-7, 2005

Markers of treatment failure in hospitalised community acquired pneumonia. Yearbook of Pulmonary Disease 2009: 237-238, 2009

Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 63(5): 447-452, 2008

Community-acquired pneumonia: judicious use of antibiotics or treatment failure?. Hospital Pediatrics 3(2): 180-181, 2014

Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. Bmc Infectious Diseases 5(): 106-106, 2005

Early and late treatment failure in community-acquired pneumonia. Seminars in Respiratory and Critical Care Medicine 30(2): 154-160, 2009

Community acquired pneumonia: prognosis assessment and therapy. When must the patient be hospitalized?. Mmw Fortschritte der Medizin 153(1-2): 16-16, 2014

Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. Journal of Thrombosis and Thrombolysis 35(2): 147-154, 2013